Samsung Biologics Expands Collaboration with LigaChem Biosciences for ADC Development
Thursday, January 09, 2025
Samsung Biologics has announced the expansion of its partnership with LigaChem Biosciences to advance the development of antibody-drug conjugates (ADCs).
LigaChem Biosciences focuses on developing ADC candidates targeting solid tumours.
The collaboration will centre on Samsung Biologics’ new ADC-dedicated facility, which features a segregated suite and a 500-litre reactor designed to support ADC development and manufacturing.
This facility enhances Samsung Biologics’ existing expertise in large-scale antibody production and process engineering, offering services that span from late discovery to ADC conjugation.
Through this extended partnership, Samsung Biologics aims to further strengthen its capabilities in ADC development and manufacturing, ensuring high-quality therapeutic solutions are delivered to the market.
LigaChem Biosciences seeks to leverage this collaboration to enhance its supply chain for ADC drugs and accelerate the progress of its pipeline, bolstering its competitiveness in the global ADC market.
In addition to this collaboration, Samsung Biologics has been investing in innovative biotech companies through the Samsung Life Science Fund, focusing on ADC linker technologies, toolboxes, and protein engineering.
These efforts underscore the company’s commitment to advancing ADC therapies and supporting clients in bringing innovative treatments to patients efficiently.
Source: samsungbiologics.com
